A Phase 3 study to assess the efficacy and safety of JTZ-951 in ESA naive anemic patients with chronic kidney disease receiving hemodialysis <anemia correction / maintenance study>

Trial Profile

A Phase 3 study to assess the efficacy and safety of JTZ-951 in ESA naive anemic patients with chronic kidney disease receiving hemodialysis <anemia correction / maintenance study>

Recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs JTZ 951 (Primary)
  • Indications Anaemia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Japan Tobacco
  • Most Recent Events

    • 02 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top